FROM THE FAMILY PRACTICE INQUIRIES NETWORK
Is Fluoxetine an Effective Therapy for Weight Loss in Obese Patients?
Am Fam Physician. 2003 Dec 15;68(12):2437-2438.
In patients who are obese, are selective serotonin reuptake inhibitors (SSRIs) more effective than placebo or other therapies for weight loss?
Fluoxetine (Prozac) use may result in an average, short-term weight loss of up to 3.3 kg (7 lb, 4 oz) in obese patients, but the longterm effects and maintenance of weight loss after discontinuation of the drug have not been well studied. No evidence concerning other SSRIs was found. [Strength of recommendation: B, based on low-quality systematic reviews of randomized controlled trials (RCTs)]
Safety concerns have curbed the use of many weight loss medications, notably appetite suppressants. SSRIs, initially approved for the treatment of depression, are being studied now for use in obesity treatment.
A systematic review1 of 11 studies of fluoxetine in the treatment of obesity was weakened by a failure to evaluate the quality of the included articles and by its reliance on effect size as a reported outcome. The review did use a reasonably comprehensive search strategy and a sound meta-analytic process. In the 11 studies, fluoxetine was used for an average of 28 weeks and resulted in an average weight loss of 3.3 kg. [Evidence level 2a] No long-term follow-up data were available in this review.
Another review2 reported the same information but noted, in 10 to 15 percent of cases, an occurrence of minor side effects (e.g., anxiety, diarrhea, dry mouth), and “uncommon but serious” adverse events (e.g., bleeding, granulocytopenia, seizures, hyponatremia, hepatotoxicity, serotonin syndrome, extrapyramidal effects). [Evidence level 2a]
A 1999 systematic review3 of RCTs and prospective cohort trials looked at existing treatment options for obesity. A single RCT of fluoxetine was included in the review of eight RCTs of drug therapy in combination with dietary management and appetite suppressants. Fluoxetine had no significant benefit over placebo in bringing about weight loss in the 12-month study. All of the RCTs reported that any weight lost with medication use generally was regained 12 months after discontinuation of therapy. [Evidence level 1a: systematic review]
The Agency for Health Care Research and Quality is preparing a health technology assessment on the topic of pharmacologic therapy for obesity.
Recommendations from Others
The Obesity Education Initiative guidelines4 from the National Heart, Lung, and Blood Institute do not address SSRIs in the pharmacologic management of obesity, presumably because SSRIs are not approved by the U.S. Food and Drug Administration for this use. [Evidence level 5: evidence-linked consensus guideline]
One of the consistent “concomitant therapies” in all pharmacologic weight loss studies is a program of rigorous diet and exercise. Evaluating SSRIs as weight loss therapy is a good idea, given the extent of obesity in our society. However, as safer weight loss medications are brought to the market, we must resist the temptation to concentrate solely on the numbers on the scale and continue to promote a healthy lifestyle of diet and exercise as the primary method of achieving weight control and preventing obesity.
REFERENCESshow all references
1. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obesity. 2002;26:262–73....
2. Arterburn D. Endocrine disorders/obesity. Clinical evidence. Accessed January 20, 2003, at: http://www.clinicalevidence.com.
3. Cheskin LJ. Review: most obesity treatment methods are ineffective over the long term. ACP Journal Club 1999;131:20. Comment on: Douketis JD, Feightner JW, Attia J, Feldman WF, with the Canadian Task Force on Preventive Health Care. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. CMAJ. 1999;160:513–25.
4. Obesity Education Initiative. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. NIH publication no. 98-4083. National Heart, Lung, and Blood Institute, National Institutes of Health, September 1998.
Copyright Family Practice Inquiries Network. Used with permission.
Clinical Inquiries provide answers to questions submitted by practicing family physicians to the Family Practice Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/levels_of_evidence.asp).
This series of Clinical Inquiries is coordinated for American Family Physicianby John Epling, M.D., State University of New York Upstate Medical University, Syracuse, N.Y. The complete database of evidence-based questions and answers is copyrighted by FPIN.
Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions